Dr. Heeney is on Doximity
As a Doximity member you'll join over two million verified healthcare professionals in a private, secure network.
- Gain access to free telehealth tools, such as our “call shielding” and one-way patient texting.
- Connect with colleagues in the same hospital or clinic.
- Read the latest clinical news, personalized to your specialty.
Office
300 Longwood Ave
Boston, MA 02115Phone+1 617-919-3242Fax+1 617-730-0641
Summary
- Dr. Matthew Heeney is a pediatric hematologist/oncologist in Boston, MA and is affiliated with multiple hospitals in the area, including Dana-Farber Cancer Institute, Brigham and Women's Hospital, Boston Children's Hospital, and Boston Medical Center. He received his medical degree from University of Calgary Faculty of Medicine and has been in practice 22 years. He also speaks multiple languages, including French. He is experienced in hemochromatosis, iron deficiency anemia, pediatric hematology / oncology, sideroblastic anemia, and pediatric sickle cell anemia.
Education & Training
- Duke University HospitalFellowship, Pediatric Hematology/Oncology, 1999 - 2002
- McGill University Faculty Medicine HospitalPediatrics, 1995 - 1999
- University of Calgary Faculty of MedicineClass of 1995
Certifications & Licensure
- MA State Medical License 2002 - 2025
- VA State Medical License 2002 - 2004
- NC State Medical License 1999 - 2002
- American Board of Pediatrics Pediatric Hematology-Oncology
Awards, Honors, & Recognition
- Fellow (FAAP) American Academy of Pediatrics
Clinical Trials
- Inhaled Nitric Oxide for Pediatric Painful Sickle Crisis Start of enrollment: 2005 Apr 01
- Priapism in Boys and Men With Sickle Cell Disease - Demographics, Characteristics and Prevalence Start of enrollment: 2005 Aug 01
- Adenosine 2A Agonist Lexiscan in Children and Adults With Sickle Cell Disease Start of enrollment: 2010 Apr 01
- Join now to see all
Publications & Presentations
PubMed
- Sustained increase in annual transcranial Doppler screening rates in children with sickle cell disease: A quality improvement project.Jeffrey G Edwards, Adam P Yan, Ramy Yim, Mo Oni, Matthew M Heeney
Pediatric Blood & Cancer. 2024-08-01 - The Risk of Kidney Injury in Patients With Sickle Cell Disease Treated With Ketorolac for Acute Pain.Emily M Harris, Morohuntodun O Oni, Carolina Donado, Matthew M Heeney, Jean Solodiuk
Journal of Pediatric Hematology/oncology. 2024-07-01 - 1 citationsIncreasing COVID-19 Vaccination Rates for Children With Sickle Cell Disease.Adam P Yan, Natasha M Archer, Dianne Arnold, Eileen Hansbury, Matthew M Heeney
Pediatrics. 2023-10-01
Journal Articles
- The Phenotypic Spectrum of Germline YARS2 Variants: From Isolated Sideroblastic Anemia to Mitochondrial Myopathy, Lactic Acidosis and Sideroblastic Anemia 2Matthew M Heeney, Gregory A Hale, David P Steensma, Mark D Fleming, Colin A Sieff, Lee M Hilliard, Sylvia S Bottomley, Janet L Kwiatkowski, Haematologica
Press Mentions
- Researchers Report New Opportunities to Improve Quality of Life for People with Non-Malignant Blood DisordersDecember 7th, 2024
- A Sickle Cell First: Base Editing, a New Form of Gene Therapy, Leaves Patient Feeling 'More Than Fine'December 7th, 2024
- VIDEO: Dosing Evaluation Trial Aims to ‘Broaden the Label’ for Sickle Cell TreatmentDecember 20th, 2021
- Join now to see all
Professional Memberships
- Fellow
Other Languages
- French
Viewing the full profile is available to verified healthcare professionals only.
Find your profile and take control of your online presence: